Two years after spinning off its $15 billion consumer health unit as Kenvue, Johnson & Johnson is slimming down again by ...

Nascent cardiovascular biotech Kardigan is continuing its bumper year with a pulse-quickening $254 million series B ...

Denali Therapeutics has become the latest on a growing list of biotechs to experience an FDA review delay in recent months. | ...

After walking away from cell therapy and narrowing its focus to just three modalities, Takeda is doubling down on its ...

Gilead Sciences and Arcus Biosciences’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of close to ...

Excellergy has emerged with $70 million and an investigative drug class in its portfolio, part of its ambitious mission to ...

“Our findings show that RNA-based testing can uncover hidden risks in multiple myeloma that DNA tests alone miss,” study ...

Moderna has shared some of the phase 1/2 data that persuaded it to expand and p | Moderna has shared some of the phase 1/2 ...

In February, the biotech reported improvements in 10 of 11 children who received DB-OTO. The AAV gene therapy, which ...

Tvardi Therapeutics has failed its first big test as a public company. | Tvardi Therapeutics has failed its first big test as a public company. Months after joining Nasdaq, the biotech has reported ...

Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding ...